N/A N=30,597 European Active Surveillance Study of Women Taking Hormone Replacement Therapy (HRT)
Menopausal Symptoms
Primary: Venous Thromboembolism (e.g., Deep Venous Thrombosis and Pulmonary Embolism) — 24; 74; 21; 12 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy
Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose, Dose Limiting Toxicity — 0; 0; 0; 0 participants
N/A N=84 Central Auditory Processing Disorders Associated With Blast Exposure
Central Auditory Processing Disorder · Traumatic Brain Injury · Hearing Loss
Primary: Audiological Test Results — 10.8; 6.6 decibels Hearing Level
Phase 3 N=196 Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease
Kawasaki Disease
Primary: The Number of Subjects in Each Arm That Have Persistent or Recrudescent Fever 24 Hours After Completion of the Intravenous Immunoglobulin (IVIG) Infusion — 11; 11…
Phase 4 N=24 Effect of Pioglitazone on TIMP-3 and TACE in Type 2 Diabetes
Type 2 Diabetes
Primary: Whole Body Insulin Sensitivity During the Euglycemic Insulin Clamp — 3.2; 3.01; 3.4; 3.7 Mg. of glucose/kg body w./mUxl ins. — p=0.04
Phase 3 N=183 Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)
Branch Retinal Vein Occlusion
Primary: Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF — 24; 48 participants — p=0.0003
Phase 2 N=409 Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
Acquired Bleeding Disorder · Cardiac Surgery Requiring Cardiopulmonary Bypass
Primary: Percentage of Subjects Avoiding Any Allogeneic Transfusions for Seven Days Post-operative or Until Discharge, Whichever Came First — 35.2; 35.7; 34.1; 64.8 percentage…
N/A N=34 Inflammation and Insulin Resistance in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale
N/A N=38 Feasibility Study of a Modular Control to Range System in Type 1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Primary: Hypoglycemic Events — 1.08; 0.4; 1.4; 1.6 events/admission per patient
Phase 4 N=21 A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs.
Rheumatoid Arthritis
Primary: Mean Percentage of Cells Staining Positive for Annexin V Binding in Apoptosis — 8.95; 7.36; 8.45; 12.43 percentage of cells staining positive — p=0.308
Phase 4 N=80 Dexmedetomidine to Prevent Agitation After Free Flap Surgery
Agitation · Delirium
Primary: Agitation in PACU — 15; 18; 4; 12 participants
Phase 2 N=21 Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Participant Responses — 2; 8; 4; 6 participants
Phase 2 N=352 Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)
Psoriasis · Plaque-type Psoriasis
Primary: Core Study: Percentage of Participants Who Achieved a 75% Improvement (Response) in Psoriasis Area and Severity Index (PASI) at Week 16 — 5.7; 11.2; 28.7; 40.9…
N/A N=150 Return of Continence Following Robot-Assisted Radical Prostatectomy With or Without a Urethrovesical Sling
Urinary Incontinence · Prostate Cancer
Primary: Number of Continent Patients Post Prostatectomy — 37; 32 participants
N/A N=402 Evaluation of Surgisis Gold Graft for Incision Reinforcement After Open Bariatric Surgery
Hernia · Obesity
Primary: Incisional Hernia — 32; 38 participants — p=0.60